Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 19, Pages -Publisher
MDPI
DOI: 10.3390/jcm10194409
Keywords
heart failure with reduced ejection fraction; novel medical therapy; hospitalization; mortality; morbidity
Categories
Ask authors/readers for more resources
Heart failure with reduced ejection fraction (HFrEF) is a clinical condition associated with impaired cardiac contractility, characterized by pathological left ventricular (LV) remodeling and progressive dilatation, leading to adverse clinical outcomes. Recent novel pharmacological therapies, such as ARNI, SGLT2i, vericiguat, and omecamtiv mecarbil, have shown improved clinical benefits when added to standard care, leading to a significant paradigm shift in the medical treatment of HFrEF. These therapies have emerged at an exciting rate, with landmark clinical trials demonstrating their additive clinical benefits in patients with HFrEF and providing a suggestive paradigm of pharmacological therapy according to the 2021 ESC guidelines.
Heart failure with reduced ejection fraction (HFrEF) is a clinical condition associated with cardiac contractility impairment. HFrEF is a significant public health issue with a high morbidity and mortality burden. Pathological left ventricular (LV) remodeling and progressive dilatation are hallmarks of HFrEF pathogenesis, ultimately leading to adverse clinical outcomes. Therefore, cardiac remodeling attenuation has become a treatment goal and a standard of care over the last three decades. Guideline-directed medical therapy mainly targeting the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) has led to improved survival and a reduction in HF hospitalization in this population. More recently, novel pharmacological therapies targeting other pathways implicated in the pathophysiology of HFrEF have emerged at an exciting rate, with landmark clinical trials demonstrating additive clinical benefits in patients with HFrEF. Among these novel therapies, angiotensin receptor-neprilysin inhibitors (ARNI), sodium-glucose cotransporter-2 inhibitors (SGLT2i), vericiguat (a novel oral guanylate cyclase stimulator), and omecamtiv mecarbil (a selective cardiac myosin activator) have shown improved clinical benefit when added to the traditional standard-of-care medical therapy in HFrEF. These new comprehensive data have led to a remarkable change in the medical therapy paradigm in the setting of HFrEF. This article will review the pivotal studies involving these novel agents and present a suggestive paradigm of pharmacological therapy representing the 2021 European Society of Cardiology (ESC) guidelines for the treatment of chronic HFrEF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available